Gamma-aminobutyric acid type A receptor alpha-1 subunit-containing complex (GABRA1-GABAA)

The Gamma-aminobutyric acid type A (GABAA) receptor alpha-1 subunit-containing complex is a pentameric ligand-gated chloride channel that mediates fast inhibitory neurotransmission in the central nervous system (UniProt P14867). The benzodiazepine binding site, located at the interface of the alpha and gamma subunits, is a major pharmacological target for sedative, hypnotic, and anticonvulsant drugs (Sigel & Ernst, 2018). Receptors containing the alpha-1 subunit are the most prevalent GABAA subtype in the brain and are primarily responsible for the sedative, anticonvulsant, and amnestic effects of benzodiazepines (Rudolph & Knoflach, 2011). Dysregulation of these receptors is implicated in sleep disorders, epilepsy, and the pathophysiology of alcohol dependence (StatPearls, Benzodiazepines). Drugs like zolpidem selectively target alpha-1-containing receptors to treat insomnia while minimizing some side effects associated with broader GABAA modulation (PubChem). However, chronic activation can lead to tolerance and physical dependence, posing significant clinical challenges (NIH, MedlinePlus). Understanding the specific role of the alpha-1 subunit allows for the development of more targeted therapies with improved safety profiles.

Other names

Alpha-1-containing GABAA receptorGABRA1-containing receptor complexBenzodiazepine receptor type 1 (BZ1)Omega-1 receptorGABRA1

Positive allosteric modulation (PAM) at the benzodiazepine binding site (alpha-gamma interface), which increases the frequency of chloride channel opening when GABA is bound, leading to hyperpolarization of the postsynaptic neuron (Sigel & Ernst, 2018; StatPearls).